FibroBiologics, Inc.
FBLG
$0.26
-$0.02-5.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.28% | -8.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -48.59% | 12.20% | |||
| Operating Income | 48.59% | -12.20% | |||
| Income Before Tax | 43.86% | -24.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.86% | -24.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.86% | -24.04% | |||
| EBIT | 48.59% | -12.20% | |||
| EBITDA | 49.25% | -12.26% | |||
| EPS Basic | 59.81% | -11.19% | |||
| Normalized Basic EPS | 59.79% | -11.14% | |||
| EPS Diluted | 59.81% | -11.19% | |||
| Normalized Diluted EPS | 59.79% | -11.14% | |||
| Average Basic Shares Outstanding | 39.72% | 11.48% | |||
| Average Diluted Shares Outstanding | 39.72% | 11.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||